In breast cancer cells, I3C and ICZ treatments decreased vimentin and FAK levels, reduced the activity of MMP2 and MMP9, and increased the E-cadherin levels, resulting in an inhibition of migration through the epithelial-to-mesenchymal transition (EMT) process [148]. Here, CDH1 is linked to breast carcinoma.